Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Opus GeneticsIRD +27.62%20 Cash-to-Debt is 2.45 as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates IRD with a GF Score™ of 20/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,397 Biotechnology companies, Opus Genetics ranks worse than 64.35% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Opus Genetics's cash to debt ratio for the quarter that ended in Jun. 2026 was 2.45.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Opus Geneticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Opus Genetics's Cash-to-Debt or its related term are showing as below:
IRD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.27 Med: No Debt Max: No Debt
Current: 2.45
During the past 7 years, Opus Genetics's highest Cash to Debt Ratio was No Debt. The lowest was 0.27. And the median was No Debt.
IRD's Cash-to-Debt is ranked worse than 64.35% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs IRD: 2.45
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Opus Genetics Cash-to-Debt Related Terms
Opus Genetics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Opus Genetics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Opus Genetics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Opus Genetics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (IRD) has a Cash-to-Debt of 2.45 as of Jun. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Opus Genetics' Cash-to-Debt has ranged from 0.27 to 10,000.00. According to the industry distribution chart, Opus Genetics ranks #899 out of 1397 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Opus Genetics' Cash-to-Debt too high?
Opus Genetics' current Cash-to-Debt of 2.45 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Opus Genetics' value of 2.45 is 63.5% below this industry median. Based on the distribution chart, Opus Genetics ranks #899 out of 1397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Opus Genetics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Cash-to-Debt compare to OBIO and CYDY?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #899 out of 1397 companies for Cash-to-Debt. This places Opus Genetics in the lower half of its industry. The industry median Cash-to-Debt is 6.72. Opus Genetics' value of 2.45 is 63.5% below this benchmark. Historically, Opus Genetics' own Cash-to-Debt has ranged from 0.27 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 6.72, Opus Genetics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opus Genetics's current Cash-to-Debt of 2.45 is 63.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current Cash-to-Debt is 2.45, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $5.55 — trading 1880.4% above its estimated fair value. The current Cash-to-Debt is 2.45, which is 100% below median its 10-year median of 10,000.00 and 63.5% below the Biotechnology industry median of 6.72. Opus Genetics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Opus Genetics (IRD), the current Cash-to-Debt is 2.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $5.55 is trading 1880.4% above its estimated GF Value™ of $0.28.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
Cash-to-Debt: 2.45 (100% below median its 10-year median of 10,000.00)
GF Value™: $0.28 vs. price of $5.55 (1880.4% above fair value)
Industry Position: 63.5% below the Biotechnology median (#899 of 1397)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
20GF Score
Get the complete analysis for IRD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
